iRadimed Corporation Stock News

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.

Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential. The post 7 Safe Stocks to Rely On When the Market Swerves appeare

IRadimed Corporation (NASDAQ:IRMD) declares $1.00/share special dividend.Payable Feb. 24; for shareholders of record Feb. 17; ex-div Feb.

WINTER SPRINGS, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per

iRadimed Corporation (NASDAQ: IRMD ) reported Q4 FY21 sales of $11.87 million , up 39% Y/Y, beating the consensus of $11.63 million. Sales from MRI devices increased 50% to $7.97 million. The gross margin improved from 75.3% to 77.9%, operating margin expanded from 7.6% to 26.2%. The Company posted a net income of $3.89 million, up from $0.64 million a year ago. Adjusted EPS … Full story available on Benzinga.com

IRadimed Corporation (IRMD) CEO Roger Susi on Q4 2021 Results - Earnings Call Transcript

iRadimed press release (IRMD): Q4 Non-GAAP EPS of $0.33.Revenue of $11.87M (+38.8% Y/Y).For FY2022, the company expects to report revenue of $51.4M to $52.2M and non-GAAP diluted EPS

WINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) --  iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) me

WINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) -- iRadimed Corporation (the Company) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (MRI) medical devices and the only known provider of a non-magnetic intravenous (IV) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months and year ended December 31, 2021.